Ozempic, Wegovy among drugs subject to Medicare price controls

Highly coveted weight-loss related diabetes drugs produced by Danish drugmaker Novo Nordisk are among the medications that will be subject to price controls by Medicare. On Friday, the Centers for Medicare & Medicaid Services (CMS) released the second list of prescription medications covered under Medicare Part D. The list has 15 drugs, touted as an effort to help lower the financial burden for millions of patients who are 65 years and older. It includes Novo Nordisk's weight loss and diabetes drugs Wegovy ...